Bookmark and Share

Compound Summary for: CID 16220172

Ivacaftor

Also known as: VX-770; Kalydeco; 873054-44-5; VX 770; UNII-1Y740ILL1Z; N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Molecular Formula: C24H28N2O3   Molecular Weight: 392.49072   InChIKey: PURKAOJPTOLRMP-UHFFFAOYSA-N
Ivacaftor (also known as Kalydeco or VX-770) is a drug for the treatment of cystic fibrosis, developed by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation. FDA approved on January 31, 2012.    From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show first sub-section only
Use and Manufacturing
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _